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ABSTRACT: The American College of Radiology (ACR) Appropriateness
Criteria are evidence-based guidelines for specific clinical conditions that
are reviewed annually by a multidisciplinary expert panel. The guideline
development and revision include an extensive analysis of current medi-
cal literature from peer-reviewed journals and the application of well-
established methodologies (RAND/UCLA Appropriateness Method and
Grading of Recommendations Assessment, Development, and Evaluation
or GRADE) to rate the appropriateness of imaging and treatment proce-
dures for specific clinical scenarios. In those instances where evidence
is lacking or equivocal, expert opinion may supplement the available evi-
dence to recommend imaging or treatment. Here, we present the Appro-
priateness Criteria for cancers arising in the nasal cavity and paranasal
sinuses (maxillary, sphenoid, and ethmoid sinuses). This includes clinical
presentation, prognostic factors, principles of management, and treat-
ment outcomes. Controversies regarding management of cervical lymph
nodes are discussed. Rare and unusual nasal cavity cancers, such as
esthesioneuroblastoma and sinonasal undifferentiated carcinomas, are
included. VC 2016 American College of Radiology. Head Neck 39: 407–
418, 2017
KEY WORDS: Appropriateness Criteria, nasal cavity cancer, para-
nasal sinus cancer, esthesioneuroblastoma, sinonasal undifferentiat-
ed carcinoma
INTRODUCTION
Summary of literature review
The paranasal sinuses consist of the maxillary, ethmoid,
sphenoid, and frontal sinuses. They communicate with the
nasal cavity in the midline and all structures together form
a group of air-filled cavities where cancers can arise, grow,
and spread without encountering significant barriers to
local extension. Cancers of the paranasal sinuses and nasal
cavity are rare malignancies, accounting for 3% to 5% of
all head and neck cancers and <1% of all cancers.1–3 The
maxillary sinus is the most common site of paranasal sinus
cancers (60% to 70% of cases), followed by the nasal cavi-
ty (20% to 30%), ethmoid sinus (10% to 15%), and frontal
and sphenoid sinuses (1% to 2%). These are to be distin-
guished from skin cancers with deep erosion or nasal vesti-
bule/nasal sill cancers with posterior extension. Because of
the air space and cavities in the sinonasal region, these
cancers are generally asymptomatic in early stages and are
often not diagnosed until they are locally advanced. There
are a wide variety of tumor types within the paranasal
sinuses and nasal cavity, but, as in other locations in the
head and neck, squamous cell carcinoma predominates,
accounting for >80% of paranasal sinus cancers.2,4 The 5-
year overall survival (OS) in patients with squamous cell
carcinoma of the paranasal sinuses is approximately 50%,
30%, and 15% among those with localized, regional, and
distant disease, respectively.3 Tobacco use is a significant
risk factor for squamous cell carcinomas, and exposure to
wood dust, glues and adhesives, and pollutants is associat-
ed with adenocarcinomas.
These cancers are relatively rare, resulting in a conse-
quent lack of well-designed prospective trials to guide
therapy. Therefore, most treatment recommendations are
based on retrospective studies. Unfortunately, these
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reports have included a mix of disease sites and stages;
they often represent varied histologies. Additionally,
many of the large retrospective series include patients
treated over many decades, with changes in diagnostic
imaging, surgical techniques, radiotherapy (RT) techni-
ques and doses, and use of systemic agents further cloud-
ing the applicability of these studies. Hence, definitive
treatment recommendations regarding a specific subsite
with a specific histology are hard to derive. Finally, many
studies present significant institutional bias.
Anatomy and patterns of spread
The paranasal sinuses and nasal cavity occupy the mid-
face and are bounded by the skull base, palate, and infra-
temporal fossa. Although the paranasal sinuses have
defined boundaries, the degree of pneumatization is wide-
ly variable, which can affect the ability of a tumor to
invade the surrounding structures. These adjacent struc-
tures are generally responsible for the signs and symp-
toms that prompt evaluation and diagnosis, heralding an
advanced stage.
The maxillary sinus is the largest of the paranasal
sinuses and is bounded by the floor of the orbit superior-
ly, the lateral wall of nasal cavity medially, the zygomatic
process and deep masseteric space laterally, and the alve-
olar processes and palate inferiorly. Tumors that invade
the orbit lead to proptosis, diplopia, and other visual
changes. Trismus, facial swelling, tooth pain, and midface
or jaw numbness signify spread to the infratemporal fos-
sa, pterygopalatine fossae, or masseteric space. The max-
illary sinus can be divided into 2 portions by the
imaginary Ohngren line, drawn from the medial canthus
to the angle of the mandible. This line separates the max-
illary sinus into suprastructure (posterosuperior portion)
and infrastructure (anteroinferior portion), a historically
important distinction. Although this designation is not
part of current staging, it is clinically useful for providing
a framework to predict extension outside the sinus cavity
and it functions as a general guide to surgical resectabili-
ty. Lesions originating in the suprastructure more readily
invade the nasal cavity, ethmoid sinus, orbit, pterygopala-
tine fossa, infratemporal fossa, and skull base. Involve-
ment of these structures gives rise to a higher T
classification and may render the tumor unresectable, thus
portending a poorer prognosis. Lesions inferior to the
Ohngren line tend to invade the soft palate, mandible,
buccal mucosa, nasal cavity, and pterygopalatine space.
These lesions typically carry a lower T classification and
have a better prognosis because they are more often
resectable with uninvolved margins.
Primary nasal cavity tumors often originate on the nasal
septum or roof of the nasal vault and will usually fill the
airspace on the involved side. The nasal cavity is bounded
anteriorly by the mucocutaneous junction with the nasal
vestibular skin, posteriorly by the choana, laterally by the
turbinates and lateral nasal wall, superiorly by the skull
base, and inferiorly by the hard palate. Septal cancers
should be carefully distinguished from skin cancers origi-
nating from the nasal vestibule/sill. The pattern of cancer
spread is typically determined by the site of origin of the
tumor. For example, lesions in the superior portion of the
nasal cavity can invade the orbit through the ethmoid
sinuses and lamina papyracea and the anterior cranial fos-
sa through the cribriform plate, whereas more inferior
lesions can invade the maxillary sinuses and the palate.
Anteriorly, they can grow into subcutaneous tissue and
the overlying skin.
The ethmoid sinuses are in close proximity to critical
structures, such as those in the orbit, containing the optic
nerve laterally and optic chiasm posteriorly, and the base
of the skull. The paranasal sinuses are separated from the
orbit by the lamina papyracea. The thin lamina allows
easy access to the orbit, which can result in diplopia,
proptosis, and visual loss from relatively small tumors.
Superior extension into the anterior cranial fossa is also
easy because of the poor tumor barrier provided by the
fenestrated cribriform plate. Superior extension is facili-
tated by the olfactory nerves, which cross the cribriform
plate, providing intracranial access. In addition, ethmoid
sinus cancers often extend to involve the adjacent maxil-
lary sinus.
The sphenoid sinus is a midline structure and cancers
arising here often extend laterally to involve the adjacent
cavernous sinus or orbital apex. The occult nature of
these tumors often results in intracranial extension. The
frontal sinus resides within the anterior skull and is
bounded by the anterior cranial fossa and the tissues of
the forehead. The pneumatization pattern is quite variable,
even side-to-side in the same patient, and may extend lat-
erally over the orbital roof.
Lymph node involvement at the time of diagnosis is
rare for most nasal cavity and paranasal sinus malignan-
cies. The rates are generally below the 15% to 20% rec-
ommended for elective treatment. However, in patients
with squamous cell and poorly differentiated carcinoma
of the maxillary sinus, the cumulative macroscopic and
microscopic incidence of nodal disease can be as high as
30%. In a report of patients with predominantly T3 and
T4 cancers of the maxillary sinus, the regional recurrence
rate was 38% in patients with squamous cell and poorly
differentiated carcinoma in the absence of elective neck
treatment.5 The most commonly involved lymph nodes
are ipsilateral level Ib and level II lymph node groups.
Contralateral nodal involvement is very rare. Le et al6
reported that the overall risk of nodal involvement at
diagnosis and on follow-up was 28% for squamous cell
carcinoma of the maxillary sinus. The risk of lymph node
involvement correlates with advanced T classification and
inferior involvement of the alveolar ridge, gingivobuccal
sulcus, and palate. In the above series, all patients with
nodal involvement had T3 to T4 disease. This is in con-
trast to nasal, ethmoidal, sphenoid, and frontal sinus can-
cers, which rarely metastasize regionally. Extension
outside the confines of the involved sinus (higher T clas-
sification) allows access to more robust lymphatics and
may lead to a higher rate of nodal disease. In addition to
levels Ib and II, the retropharyngeal nodes need to be
assessed for all paranasal sinus tumors and the parotid
nodes are potential first-echelon nodes in cases of mid-
face or lateral extension. Nasal cavity cancers also have
low nodal metastatic rates, and 1 series of primary nasal
cavity cancers reported a rate of subsequent neck recur-
rence of 7% in patients without neck treatment.7
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Clinical presentation and patient evaluation
The paranasal sinuses and nasal cavity are unique in
that they largely consist of air-filled spaces. This allows
for insidious growth of a tumor with relatively few obvi-
ous symptoms until the tumor reaches an advanced stage
after invading adjacent structures. For sinonasal malignan-
cies, presenting symptoms are usually nonspecific and
may mimic sinusitis until lesions extend into the sur-
rounding tissues. Common symptoms include nasal
obstruction, nasal discharge, epistaxis, a visible tumor
mass, facial pain or discomfort, or hypoesthesia of the
midface. The diagnosis requires a high index of suspi-
cion.8 The symptoms and signs resulting from local
extension outside the involved sinus can include facial
swelling and pain from anterior extension; proptosis, dip-
lopia, and orbital pain with orbital invasion; or toothache,
unhealed tooth socket after dental extraction, a mass in
the upper gum, or an oroantral fistula from inferior
extension.
A full history and physical examination should be per-
formed with emphasis on careful examination of cranial
nerve function. Endoscopic nasal examination allows
assessment of local extension of the disease. Imaging
studies should include dedicated thin-cut multiplanar CT
and MRI of the sinuses. CT offers better information on
bone invasion and MRI offers better information about
the involvement of soft tissue, nerves, skull base, and
brain, and better differentiation of fluid from solid tumor.
Tissue biopsy must be performed for definitive pathologic
diagnosis and careful endoscopic evaluation can be per-
formed at that time.
Prognostic factors
One of the most important prognostic factors for these
tumors is the local extension of the tumor, signified by
the American Joint Committee on Cancer T classification.
T3 and T4a tumors are locally advanced by virtue of
invasion of structures in the immediate vicinity but are
considered surgically resectable. Tumors classified as T4b
tumors are surgically unresectable as they invade the
orbital apex, dura, brain, middle cranial fossa, and cranial
nerves other than CN V2, nasopharynx, or clivus. The
local extent determines the ability to perform a surgical
resection with clear margins and the structures that must
be sacrificed to achieve them. The potential loss of struc-
tures, such as the eye with maxillary sinus cancer,
although technically feasible and appropriate, may over-
whelm the patient and lead to rejection of surgical man-
agement. Adequate counseling must be provided in order
to permit informed decisions on the part of the patient.
Other negative prognostic factors for nasal cavity and
paranasal sinuses include advanced N classification, intra-
cranial tumor infiltration, or infiltration of the pterygopa-
latine fossa, skull base, dura, cribriform plate, or
orbits.9–12
Principles of management and treatment outcomes
Management of nasal cavity and paranasal sinus malig-
nancies should involve a multidisciplinary approach with
the inclusion of head and neck/skull base surgeons, neuro-
surgeons, radiation oncologists, medical oncologists, and
neuroradiologists. All cases must be discussed and
reviewed by a panel of these experts and the role and
sequencing of each treatment modality must be deter-
mined. If surgery is to be performed, upfront involvement
of the reconstructive team, including plastic surgeons,
oral surgeons, and prosthodontists, is also crucial.
Surgery
Surgical resection of the primary cancer remains the
primary modality of therapy for paranasal sinus cancers.
The type of procedure varies for the primary site and can
include an open approach, an endoscopic approach, or a
combination of the two. Traditional surgical approaches
have been performed through external-access incisions
(lateral rhinotomy, bicoronal flap, or a combination of the
two), and such approaches can lead to local complica-
tions. Intraoral approaches to the maxillary sinus and pal-
ate are often adequate for infrastructure, nasal floor, and
inferior septal tumors. Such resections are distinct from
the resections of advanced tumors or those involving the
superior nasal vault and skull base. Reconstruction of
these areas was typically not performed, primarily to
facilitate disease monitoring, and rehabilitation was
instead left to prosthodontics and obturator placement.
Unpredictable scarring of the midface structures would
often occur and implants used to reconstruct the orbital
floor were often extruded. Additionally, larger defects in
the hard palate often led to chronic challenges with obtu-
rator retention, given the limited bone and soft-tissue sup-
port. The use of free tissue transfer has improved these
outcomes because the defects are closed and the remain-
ing structures (orbit, dura, etc.) are well supported by the
reconstruction. If bone is included in the free tissue trans-
fer, such reconstruction can also replace the bony alveolar
ridge to help facilitate dental restoration or prosthetic
retention. When possible, free tissue transfer should be
the default reconstructive option. Inferior maxillectomy
defects, however, remain particularly amenable to obtura-
tor reconstruction for patients in whom free tissue transfer
is either not appropriate or not desired. These procedures
remain important options, particularly in the case of recurrent
disease, but these tumors are more frequently managed
through minimally invasive endoscopic techniques.
Current minimally invasive surgical techniques with
immediate reconstruction have altered the postoperative
landscape for these patients. Open craniofacial resections,
traditionally used for tumors involving the cribriform
plate, have been reported to have rates of postoperative
morbidity approaching 40% and mortality rates of approx-
imately 5%.13,14 Widespread adoption of endoscopic sinus
surgery for benign disease led to the evolution of endo-
scopic resection of sinonasal tumors. A recent meta-
analysis of 47 studies with 453 patients evaluated various
surgical approaches, including endonasal, cranionasal, and
craniofacial resections.15 The authors noted a selection
bias for the surgeries performed, with a larger proportion
of lower-grade smaller tumors being treated endoscopi-
cally. The local recurrence rates in the endoscopic, cra-
nionasal, and craniofacial groups were 8%, 16.7%, and
22%, respectively. Similar experiences have been
reported by others.16,17 Current endoscopic techniques
allow resection of all aspects of the paranasal sinuses
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and cranial base, including intracranial tumor resection,
dural resection, and complex reconstruction to achieve
negative margins while minimizing cerebrospinal fluid
leak and other complications. Endoscopic skull base sur-
gery for sinonasal cancers has gained increasing accep-
tance and is now practiced at many centers. Smaller
tumors involving the maxillary infrastructure do not
require such technical options and are appropriately man-
aged through anterior or transoral “open” techniques
with excellent results and minimal morbidity. Debilitat-
ing defects are no longer routine and soft-tissue coverage
of the resected field and adjacent skull base has reduced
the cosmetic consequences of adjuvant therapy (see Vari-
ant 1).
Even though the majority of patients present with local-
ly advanced (T3–T4) disease, surgical resection must be
considered as part of the initial management whenever
possible. There is also interest in exploring the role of
neoadjuvant chemotherapy to make the tumor more ame-
nable to surgical resection. This topic is discussed below.
Many retrospective series have compared the outcomes of
patients treated with surgery followed by adjuvant RT
versus RT alone. A selection bias toward comparatively
lower classification and less-invasive cancers may be pre-
sent in patients who undergo initial surgery. Jansen et al18
identified 6 parameters that were associated with higher
likelihood to recommend RT alone: clinical T4 classifica-
tion, radiological evidence of skull base invasion, age
>65 years, radiological evidence of nasopharynx inva-
sion, clinical suspicion of palate invasion, and radiologi-
cal evidence of skin invasion. As skull base surgery has
evolved, however, surgical resection of advanced tumors
is more commonplace, including those previously defined
as “unresectable” (see Variant 2 and Variant 3).
At the University of Florida between 1964 and 2005,
109 patients with nasal cavity and paranasal sinus cancers
(excluding maxillary sinus) were treated with curative
intent.19 Fifty-six patients were treated with definitive RT
and 53 with surgery and RT. Patients who received
combined-modality therapy had a 5-year local control rate
CLINICAL CONDITION: Carcinoma of the maxillary sinus–Resectable early stage.
VARIANT 1. cT1-T2N0M0 maxillary sinus squamous cell carcinoma.
Treatment Rating Comments
Surgery
Surgery should be performed 9 See Refs. 19, 20, 21. Studies suggest better
outcomes with the addition of surgery.
Inferior maxillectomy 8
Ipsilateral selective neck dissection (I–III) 4
Bilateral selective neck dissection (I–III) 2
Radiation
Definitive RT alone 5 See Refs. 19, 20, 21. Studies suggest better
outcomes with the addition of surgery.
Definitive RT and concurrent chemotherapy 4
Adjuvant RT alone in the absence of negative
pathologic features (eg, lymphovascular invasion,
perineural invasion, positive margins)
3
Adjuvant RT with concurrent chemotherapy in the
absence of positive margins or extracapsular extension
2
Preoperative RT followed by surgery 2
If adjuvant RT is necessary based on surgical pathology review:
Radiation technique
3D conformal therapy 5
IMRT 9 Proton therapy may be considered in cases in
which normal tissue constraints to critical structures
(eg, optic nerves, optic chiasm, spinal cord,
brainstem, etc.) are not achievable using standard IMRT
techniques. See Refs. 25, 26, 28, 29, 30.
Target volume
Primary tumor only 8 See Refs. 5, 6, 43, 44 for risk of neck failure with or
without elective nodal irradiation.
Primary tumor and ipsilateral neck 5 This option may be appropriate but there was disagreement
among panel members on the appropriateness rating as
defined by the panel’s median rating.




70 Gy 5 This option may be appropriate but there was disagreement
among panel members on the appropriateness rating as
defined by the panel’s median rating.
Rating scale: 1, 2, and 35 usually not appropriate; 4, 5, and 65may be appropriate; 7, 8, and 95 usually appropriate.
Abbreviations: RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
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CLINICAL CONDITION: Carcinoma of the maxillary sinus—Resected advanced stage.
VARIANT 2. pT3-T4aN0M0 maxillary sinus squamous cell initially treated with total maxillectomy, ipsilateral levels I–III selective neck dissection, and a




Adjuvant RT with concurrent chemotherapy 3 If margins are positive, this should be considered. See Refs. 33, 34 for other
head and neck sites.
Induction chemotherapy before surgery 4 See Refs. 35, 36, 37.
Radiation technique
3D conformal therapy 5
IMRT 8 Proton therapy may be considered in cases in which normal tissue constraints
to critical structures (eg, optic nerves, optic chiasm, spinal cord, brainstem,
etc.) are not achievable using standard IMRT techniques. See Refs. 25, 26,
28, 29, 30.
Target volume
Primary tumor only 7
Primary tumor bed and ipsilateral neck 6 See Refs. 5, 6, 43, 44 for risk of neck failure with or without elective nodal
irradiation.





Rating scale: 1, 2, and 35 usually not appropriate; 4, 5, and 65may be appropriate; 7, 8, and 95 usually appropriate.
Abbreviations: RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
CLINICAL CONDITION: Carcinoma of the maxillary sinus—Unresectable.
VARIANT 3. cT4bN0M0 maxillary sinus squamous cell carcinoma invading the middle cranial fossa and orbital apex.
Treatment Rating Comments
Surgery
Surgery should be performed 5 This option may be appropriate but there was disagreement among panel members on
the appropriateness rating as defined by the panel’s median rating.
Nasal endoscopic resection 2
Radiation
Definitive RT alone 5
Definitive RT and concurrent chemotherapy 8 See Ref. 38.
Preoperative RT followed by surgery 3
Preoperative RT and concurrent
chemotherapy followed by surgery
4
Radiation technique
3D conformal therapy 4
IMRT 9 Proton therapy may be considered in cases in which normal tissue constraints to critical
structures (eg, optic nerves, optic chiasm, spinal cord, brainstem, etc.) are not
achievable using standard IMRT techniques. See Refs. 25, 26, 28, 29, 30.
Target volume
Primary tumor only 5 This option may be appropriate but there was disagreement among panel members on
the appropriateness rating as defined by the panel’s median rating.
Primary tumor and ipsilateral neck 8 See Refs. 5, 6, 43, 44 for risk of neck failure with or without elective nodal irradiation.
Primary tumor and bilateral neck 5 This option may be appropriate but there was disagreement among panel members on
the appropriateness rating as defined by the panel’s median rating.
Definitive radiation dose
60 Gy 3
66 Gy 5 This option may be appropriate but there was disagreement among panel members on




Induction chemotherapy followed by RT 5 This option may be appropriate but there was disagreement among panel members on
the appropriateness rating as defined by the panel’s median rating. See Refs. 36, 37.
Intra-arterial chemotherapy 3 See Refs. 41, 42.
Rating scale: 1, 2, and 35 usually not appropriate; 4, 5, and 65may be appropriate; 7, 8, and 95 usually appropriate.
Abbreviations: RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
ACR APPROPRIATENESS CRITERIA NASAL CAVITY AND PARANASAL SINUS CANCER
HEAD & NECK—DOI 10.1002/HED MARCH 2017 411
of 84%, compared to 43% in those treated with RT alone.
Other reports, each with more 200 patients, from Dul-
guerov et al9 and Guntinas–Lichius et al,11 also confirm
the benefit of combining surgery and RT for locally
advanced sinonasal cancers.
Because of the complex anatomy, proximity of critical
normal tissues, and advanced stages at presentation, com-
plete resection with negative margins may be difficult to
achieve. Resto et al20 evaluated the impact of the extent
of surgical resection in 102 patients with various histolo-
gies. Patients were characterized as having had a com-
plete resection with negative margins (20%), partial
resection with positive margins (49%), or biopsy only
(31%). RT was delivered using a combination of protons
and photons. Complete resection was found to be associ-
ated with better treatment outcomes. Although a higher
radiation dose was delivered to patients with positive
margins (75 Gy vs 68 Gy for those with negative mar-
gins), there was a strong trend toward improved local
control with greater extent of surgery. A statistically sig-
nificant improvement in disease-free survival (DFS) and
OS was noted in patients who had undergone a complete
resection. The 5-year DFS rates were 90%, 49%, and
39% for complete resection, partial resection, and biopsy-
only patients, respectively (p 5 .009). The 5-year OS
rates were 90%, 53%, and 49% for complete resection,
partial resection, and biopsy-only patients, respectively
(p 5 .02).
Radiotherapy
After resection of the primary tumor, radiation is rec-
ommended in the adjuvant setting depending on the path-
ologic risk factors. Indications for postoperative RT
include positive or close surgical margins, high-grade
tumor, perineural invasion, or concern regarding the sur-
gical margins. RT is then used to target the tumor bed,
resection cavity, any areas of residual disease, and areas
at high risk of harboring microscopic disease. Blanco
et al21 reported one of the largest series of patients treated
for maxillary sinus and ethmoid tumors. The majority of
the 206 patients were treated using conventional external-
beam RT to a median dose of 60 Gy (range, 30–81 Gy).
Radiation was delivered preoperatively (26.4%), postoper-
atively (38.7%), or as a single modality (28.3%). At a
median follow-up of 60 months, 82% of the patients had
died, 58% with recurrent or persistent primary tumor.
This resulted in 5-year DFS and OS rates of 33% and
27%, respectively. An analysis of prognostic factors iden-
tified the presence of intracranial extension, high tumor
grade, nodal involvement at diagnosis, and radiation alone
as poor prognostic factors.
Primary RT alone or with concurrent chemotherapy is
typically used in patients with unresectable disease or
those who refuse surgery.
Techniques and toxicity of radiotherapy
The techniques of RT have evolved over time. The
proximity of critical organs and structures resulted in
high rates of complications with 2D techniques.5,7,21–24
These complications included visual complications
(chronic pain and visual loss), pituitary dysfunction,
osteoradionecrosis, and frontal/temporal lobe necrosis.
The development of 3D techniques and intensity-
modulated RT (IMRT) has led to a decline in the rate of
these complications. Chen et al25 reviewed their single-
institutional experience with treating 127 patients with
cancers of the maxillary sinus and nasoethmoidal com-
plex from April 1960 to December 2005. In this very
interesting analysis, the authors noted that there was no
improvement in local control or survival over the deca-
des. However, a significant decrease in grades 3 to 4 tox-
icity was seen, with rates of 53%, 45%, 39%, 28%, and
16% for patients treated in the 1960s, 1970s, 1980s,
1990s, and 2000s, respectively. This reflected improve-
ment in RT delivery techniques. Thirty-two of 59 patients
treated with conventional RT experienced grades 3 to 4
toxicity, compared to 10 of 45 and 3 of 23 patients expe-
riencing the same when treated with 3D and IMRT tech-
niques, respectively.
However, another report addressing the same question
noted an improvement in survival over a similar time
period.9 The authors compared their outcomes in 386
patients treated between 1975 and 1995 with 16,396
patients studied in 154 previously published reports. The
most significant improvement was seen in squamous cell
and glandular histology and for maxillary and ethmoid
sinus location.
Investigators at the Ghent University Hospital treated
105 patients with sinonasal malignancies using IMRT and
reported the outcomes on 84 patients with adenocarcino-
ma, squamous cell carcinoma, esthesioneuroblastoma, and
adenoid cystic carcinoma.26 CT-based and MRI-based
planning was used to deliver 70 Gy in 35 fractions of 2
Gy each. Seven noncoplanar beams were used to treat the
planning target volume while restricting the dose to criti-
cal normal structures. The IMRT dose-volume constraints
on the optic nerves and chiasms were set at 60 Gy to
<5% of the volume. The retina was allowed to receive
55 Gy to <5% of the volume, and the dose to 50% of the
lacrimal gland was kept below 30 Gy. With a median
follow-up of 40 months, the 5-year local control and OS
rates were 70.7% and 58.5%, respectively. One patient
developed grade 3 radiation-induced visual impairment.
Temporal lobe necrosis was noted in 3 patients on long-
term follow-up.
The use of proton therapy has also been reported for
unresectable nasal cavity and paranasal sinus cancers.
Locally advanced sphenoid sinus cancers of various his-
tologies were treated to a dose of 76 Gy equivalent
(GyE),27 with 2-year local control, DFS, and OS rates of
86%, 31%, and 53%, respectively. No grades 3 to 4 visu-
al toxicities were noted. The nasal and auditory complica-
tions were also low. One patient died because of chronic
cerebrospinal fluid leak and infectious meningitis. Two
recent reports from Japan have demonstrated the ability
to use protons in these patients. Zenda et al28 treated 39
patients with unresectable paranasal sinus and nasal cavi-
ty cancers and noted a 5-year OS of 55%. Grades 3 to 5
late toxicities occurred in 13% of cases, with 1 death due
to cerebrospinal fluid leak. Another report, however, did
not note such high rates of survival with unresectable car-
cinomas. A median dose of 78 GyE was used in 17
patients, with the dose to the optic chiasm and brainstem
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kept below 50 GyE.29 The 5-year survival was 16% and
the local control rate was 17.5%. Two patients experi-
enced grade 3 or more toxicity (1 brain necrosis, 1 ipsilat-
eral blindness).
Ethmoid sinus cancers
The largest reported series for ethmoid sinus cancers is
a retrospective multicenter analysis from France, includ-
ing 418 patients with ethmoid sinus adenocarcinoma
treated between 1976 and 2001.30 The T classification
was T3 or T4 in 269 patients (64%). A worse prognosis
was noted for patients with disease involving the orbit,
dura, brain, or sphenoid sinus. The majority of the
patients (78%) underwent surgery followed by RT, and
this group was noted to have the best outcome. A total of
10 patients had lymph node involvement at presentation
and elective nodal irradiation was done in 11 patients.
The rate of recurrence was 51% at a median of 28 months
after treatment, with only 3 patients having lymph node
metastases (see Variant 4).
Sphenoid sinus cancers
Sphenoid sinus cancers are very rare. The Groupe
d’Etude des Tumeurs Te^te Et Cou published a series on
23 patients with varied histologies treated over a 16-year
period.31 In this series, cranial neuropathy at presentation
was associated with an inferior locoregional control and
OS rate, and any surgical resection, including debulking
procedures, resulted in better outcomes. The negative
prognostic implications of cranial nerve involvement were
also noted in another report of 27 patients.32
The above-referenced series for locally advanced sphe-
noid sinus cancers reported by Truong et al27 had analyzed
20 patients treated over a 14-year period. Oropharyngeal
involvement and anterior cranial fossa invasion were pre-
dictive for poor DFS rate, and brain invasion was predictive
for decreased OS.
All reports have included patients with diverse histolo-
gies, including squamous cell carcinoma, adenocarcinoma,
adenoid cystic carcinoma, chondrosarcoma, neuroendo-
crine carcinoma, lymphoma, etc. In addition, treatments
have included surgery with radiation, radiation alone, radia-
tion with chemotherapy, surgery and chemotherapy, etc.,
determined on an individual case basis.
Nasal cavity cancers
Published literature on nasal cavity/septal cancers is
predominantly in combination with paranasal sinus
CLINICAL CONDITION: Carcinoma of the nasal cavity and ethmoid sinuses.
VARIANT 4. cT2N0M0 adenocarcinoma of the ethmoid sinuses and bilateral nasal cavity.
Treatment Rating Comments
Surgery
Surgery should be performed 9 See Ref. 30.
Craniofacial resection 5
Nasal endoscopic resection 8
Radiation
Definitive RT alone 5
Definitive RT and concurrent chemotherapy 5 This option may be appropriate but there was disagreement
among panel members on the appropriateness rating as
defined by the panel’s median rating.
Adjuvant RT alone after surgical resection 6
Adjuvant RT with concurrent chemotherapy after surgical resection 5
Preoperative RT followed by surgery 3
Preoperative RT and concurrent chemotherapy followed by surgery 3
Radiation technique
3D conformal therapy 5
IMRT 8 Proton therapy may be considered in cases in which normal
tissue constraints to critical structures (eg, optic nerves,
optic chiasm, spinal cord, brainstem, etc.) are not achiev-
able using standard IMRT techniques. See Refs. 25, 26,
28, 29, 30.
Target volume
Primary tumor only 8
Primary tumor and ipsilateral neck 3 See Ref. 7 for risk of neck failure.







Induction chemotherapy followed by RT 2 See Refs.36, 37.
Intra-arterial chemotherapy 2 See Ref. 41, 42.
Rating scale: 1, 2, and 35 usually not appropriate; 4, 5, and 65may be appropriate; 7, 8, and 95 usually appropriate.
Abbreviations: RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
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cancers. One of the very few reports that addressed nasal
cavity cancers separately was published by Allen et al7
based on a retrospective review of 68 patients treated
between 1969 and 2000. These cancers were almost
equally distributed between the nasal septum (46%) and
the nasal floor/lateral wall (54%). The predominant histol-
ogy was squamous cell carcinoma (66%), followed by
adenoid cystic (18%) and adenocarcinoma (12%). Thirty-
two patients received definitive RT and the rest were
treated with surgery and radiation (3 preoperative RT and
33 postoperative RT). The authors noted better outcomes
in these patients as compared to historically reported
results when nasal cavity cancer outcomes were presented
combined with other paranasal sinus outcomes. At 5 and
10 years, the local relapse-free survival was 86% and
76%, disease-specific survival was 86% and 78%, and OS
was 82% and 62%, respectively. No difference was noted
based on nasal septum versus nasal cavity origin of these
cancers. At a median posttreatment interval of 16.8
months, neck failure was seen in 7% of cases even
though none of the patients had received elective neck
nodal irradiation.
Chemotherapy
Attempts have been made to improve upon primary RT
by the addition of induction chemotherapy and concurrent
chemotherapy with radiation. Cisplatin-based chemothera-
py is often used based on extrapolation from the results
of clinical trials in head and neck cancers of other
subsites.33,34
Induction
For patients with borderline resectable disease, preoper-
ative chemotherapy followed by surgery and postopera-
tive radiation, or chemoradiation followed by surgery, can
be used. Induction treatment can decrease the size of the
tumor and facilitate surgery, although the original margins
should be maintained. This approach may increase the
possibility of orbital preservation in select situations. Lee
et al35 reported on 19 patients treated at the University of
Chicago with induction chemotherapy. They reported an
87% response rate to the chemotherapy, and, in half of
these patients, a complete pathologic response was noted
at the time of surgery. Local control at 5 and 10 years
was 76% each, DFS was 67% each, and OS was 73% and
54%, respectively. Induction chemotherapy followed by
definitive concurrent chemoradiation for organ preserva-
tion is under investigation. Hanna et al36 recently pre-
sented their institutional experience with 46 patients
treated with induction chemotherapy. Thirty-one (67%)
had partial response to the chemotherapy. Subsequently,
14 patients had definitive radiation; 5 had chemoradia-
tion; and 8 had chemoradiation followed by planned sur-
gery for any residual disease. The rest had surgery,
usually followed by postoperative radiation. The reported
2-year OS for all patients was 67%. The 2-year OS for
those with partial response to the induction chemotherapy
was significantly better than those with progressive dis-
ease (77% vs 36%; p 5 .05). Licitra et al37 had evaluated
the role of induction chemotherapy using a combination
of cisplatin, fluorouracil, and leucovorin in 49 patients
with resectable paranasal sinus tumors. They noted a
pathologic complete response rate of 16% (8 of 49), with
these 8 patients achieving 100% OS at 3 years. However,
this regimen also resulted in significant toxicities, with 2
treatment-related deaths and 8 other patients with signifi-
cant cardiac toxicities.
Concurrent
The role of concurrent radiation and chemotherapy in
patients with unresectable stage IVB paranasal sinus and
nasal cavity tumors was reported by Hoppe et al38 in 39
patients (4 received radiation alone without chemotherapy
due to comorbidities). The majority of these patients (n 5
32) received concurrent therapy of cisplatin and a median
radiation dose of 70 Gy. Unfortunately, even with this
aggressive treatment, 22 tumors recurred within the radia-
tion field, resulting in a 5-year local progression-free sur-
vival of 21% and OS of 15%. This highlights the limited
efficacy of nonsurgical therapy in this patient group and
the poor prognosis for patients with unresectable disease.
Radiation and concurrent chemotherapy are also often
used for patients who are noted to have positive margins
on pathology after a surgical resection. This is based on
extrapolation of the results from 2 randomized trials and
their combined analysis, which showed that patients with
positive margins or extracapsular nodal extension of squa-
mous cell cancer benefitted from the additional chemo-
therapy.33,34,39 Although this extrapolation may be
appropriate for squamous cell or adenocarcinomas of the
paranasal sinuses and nasal cavity, the data are less robust
for other histologies, like adenoid cystic carcinoma. Con-
current chemotherapy with radiation in these cases must
only be recommended after careful deliberation in a mul-
tidisciplinary setting.
Intra-arterial
Intra-arterial cisplatin has been used in the treatment of
head and neck cancers. However, a randomized trial did
not demonstrate any benefit of intra-arterial chemotherapy
as compared to standard intravenous chemotherapy in oth-
er (nonparanasal sinus) head and neck squamous cell can-
cers.40 Its use in the paranasal sinuses and nasal cavity is
limited. Samant et al41 treated 19 patients (14 patients
with T4 disease) with nasal cavity and paranasal sinus
cancers using a regimen of preoperative RT to a dose of
50 Gy in 2 Gy per fraction with concurrent intra-arterial
cisplatin (150 mg/m2 per week) with systemic sodium
thiosulfate neutralization. This was followed by planned
surgery 8 weeks after completion of RT, and the 5-year
OS noted in this group was 53%. A Japanese group, using
a similar protocol, showed more promising results in 47
patients.42 Radiation was delivered at a higher dose, 65
Gy to 70 Gy, using a conventional wedge-pair technique.
Intra-arterial cisplatin, 100 to 120 mg/m2 per week for 4
weeks, was given concurrently with radiation. Surgical
resection was not performed in these patients and radia-
tion and chemotherapy was used with a definitive intent.
The 5-year local progression-free survival was 78% for
all patients, 69% for patients with unresectable (T4b) dis-
ease, and 83% for those with resectable (<T4b) disease.
Similarly, the 5-year OS rate was 69% for all patients
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and 61% and 71% for T4b and <T4b cases, respectively.
Acute toxicity was conservatively managed and there
were no treatment-related deaths. Late toxicities included
osteonecrosis (n 5 7) and brain necrosis (n 5 2). Unfor-
tunately, severe ocular/vision problems occurred in 16 of
38 patients followed for 2 years. The local control and
OS results of this approach seem superior compared with
other reported chemotherapy and radiation series,
although the toxicities are more significant. Unfortunate-
ly, the technical expertise needed to administer this tech-
nique is not easily generalizable for the purposes of
larger-scale trials.
Management of cervical lymph nodes
Elective neck management in clinically N0 necks in
nasal and paranasal sinus cancer has been controversial.
There are conflicting reports regarding the risk of regional
failures without elective neck irradiation and many surgi-
cal series do not include elective neck dissection. Dirix
et al43 reported only 4 of 122 patients (3%) originally
diagnosed with N0 disease developed a regional failure in
the neck. Others have reported higher incidences ranging
from 10% to 30%.5,6 In general, elective neck treatment
is not necessary. A recent report from China used the
superior soft-tissue imaging capabilities of MRI scans to
study the incidence of cervical and retropharyngeal lymph
node (RPLN) involvement in sinonasal cancers.44 This
study included a total of 59 patients with squamous cell
carcinoma of the maxillary sinus (n 5 19) and nasoeth-
moid region (n 5 40). Eighteen of the 59 patients had
lymph node metastases at presentation, with 11 patients
having RPLNs that were involved by radiologic criteria
(shortest axial diameter 5 mm) but not pathologically.
Three of these 11 were solely in the RPLNs and 8 were
in combination with levels Ib and II cervical lymph
nodes. Pathologic confirmation was not, however, avail-
able. The rate of lymph node metastasis in primary ade-
nocarcinoma of the ethmoid sinus seems to be very low.
As described above for the series from France, only 3
patients of >400 failed in the neck at the time of recur-
rence.30 These data demonstrate the heterogeneity inher-
ent to this disease class, given the differing lymphatic
drainage patterns of the sinuses and the differing meta-
static rates of the separate histologies.
There are, however, circumstances in which elective
nodal treatment is important. Reports have shown that, in
patients with stage T3 to T4 squamous cell and poorly
differentiated carcinoma of the maxillary sinus, elective
neck irradiation improves regional control, distant metas-
tasis, and potentially OS.5,6,14 Le et al6 reported on 97
patients with maxillary sinus cancer and noted that the 5-
year nodal recurrence was 20% for patients without elec-
tive neck irradiation and 0% for those who received neck
irradiation. Patients with neck recurrence had a signifi-
cantly higher risk for distant metastasis. The 5-year dis-
tant failure rate was 81% for patients with neck
recurrence versus 29% for those with neck control (p 5
.02). There was a trend for decreased survival with nodal
failure. The 5-year OS was 37% for patients with neck
control and 0% for patients with regional recurrence.
Jiang et al5 had reviewed their experience of 73
patients with maxillary sinus cancer treated between 1969
and 1985. There were 49 patients with T3/4N0 and 36
patients with squamous cell and undifferentiated carcino-
ma. The overall regional recurrence rate for those without
neck radiation was 33% for squamous cell and undiffer-
entiated carcinoma. None of 16 patients who received
elective neck irradiation recurred in the neck. After this
report, their institution changed its radiation techniques
and began to deliver elective neck irradiation for patients
with T2 to T4 maxillary sinus squamous cell and undif-
ferentiated carcinoma. Bristol et al45 updated the experi-
ence and compared patients treated before and after this
change. For patients with squamous cell and undifferenti-
ated carcinoma, 13 of 36 patients (36%) without neck
radiation developed regional recurrence, compared to 3 of
45 patients (7%) with elective neck irradiation (p <
.001). Those receiving elective neck irradiation had a sig-
nificant reduction in distant metastasis as well, 3% versus
20% at 5 years (p 5 .045). Although there was no differ-
ence between the groups in 5-year OS, there was a signif-
icant improvement in 5-year recurrence-free survival
(67% in treated vs 45% in untreated patients; p 5 .025).
In a Chinese study of patients with initial N0 disease,
elective nodal irradiation was delivered to levels Ib, II,
and III cervical nodes at the discretion of the treating
oncologist but not specifically to the RPLNs.44 With a
median follow-up of 28 months, there were no nodal fail-
ures seen in the 11 patients who received elective nodal
irradiation. However, among those who did not receive
elective nodal irradiation, 6 of 33 patients (18.2%)
recurred in level Ib and/or IIa. No nodal failures were
noted in the RPLNs. The authors evaluated the RT plans
and determined that the retropharyngeal space received a
median dose of 43.3 Gy (range, 28.1–61.8 Gy) even
though this area was not outlined as a clinical treatment
volume. Based on these experiences, it seems that elective
nodal irradiation should be considered in patients with T3
to T4 disease. For patients with an N0 neck who did not
receive elective neck irradiation, when they had nodal
failure, most failed at the ipsilateral level II and level Ib.
If the tumor is lateralized, elective nodal irradiation to the
ipsilateral neck should be sufficient.
As surgical techniques have improved, both with resec-
tion and reconstruction, elective neck surgery has become
more common to provide access for the vascular anasto-
mosis required for free tissue transfer. It will be interest-
ing to assess any changes in pattern of recurrence,
survival, or metastasis resulting from elective surgical
management of the neck.
Nasal cavity cancers—unusual pathologies
Esthesioneuroblastoma. Esthesioneuroblastoma (olfactory
neuroblastoma) is encountered in the superior nasal cavity
and anterior skull base. The exact site of its origin is
unknown but is thought to arise from the basal neural
cells of the olfactory epithelium. This is a rare pathology
among the already rare nasal cavity carcinomas. Clinical
presentation is similar to that described above for tumors
of the nasoethmoidal complex. One unique symptom not-
ed is anosmia, which may precede the diagnosis by a few
months. Diagnosis is established by imaging using CT or
MRI scans followed by a biopsy obtained through nasal
endoscopy.
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Esthesioneuroblastomas are staged using the Kadish46
staging system, which is divided into groups A (tumor
limited to nasal cavity), B (tumor limited to nasal cavity
and paranasal sinuses), and C (tumor extends beyond the
nasal cavity and paranasal sinuses, including base of
skull, intracranial compartment, orbit, and distant meta-
static disease). An additional group D was proposed by
Chao et al47 to include patients with cervical lymph node
metastases.
The management paradigms of this entity are similar to
those described in the general principles above. Surgery
plays a major role and most centers recommend initial
surgical resection followed by external-beam RT. The
surgical technique to be used could be either endoscopic
resection or open craniofacial resection. A meta-analysis
of 361 patients treated over a 16-year period compared
these approaches and concluded that endoscopic surgery
for esthesioneuroblastomas is a viable treatment option
with comparable survival when compared to open sur-
gery.48 A review article also examined this issue and the
authors concluded that currently available evidence sug-
gests that equivalent short-term outcomes are seen with
either surgical approach as long as the resection is com-
plete.49 Some centers have described the use of preopera-
tive RT50 or RT with concurrent chemotherapy51 with an
aim to shrink the tumor and allow better or easier surgical
resection. The advantages of preoperative RT are that it
allows delivery of a lower dose of radiation (50 Gy in 25
fractions) to the tumor and surrounding critical optic path-
way structures and that the brain can be spared the high
doses that are required postoperatively (60–70 Gy),
depending on pathologic margin status. Additionally,
tumor edges are better visualized on the MR or CT scans
(see Variant 5).
There are conflicting results on elective neck irradiation
and the use of chemotherapy. One series of 77 patients
had a nodal-only failure rate of 7% in the untreated N0
neck (local and nodal failure rate was noted in 11 of 68
patients with initially N0 neck)52; another report noted a
decrease in nodal recurrence from 44% to 0% after elec-
tive nodal irradiation.53 A review article by Zanation
et al54 examined this issue but no definite consensus
could be reached about how to manage initial N0 disease.
The role of chemotherapy is also not well defined, with a
variety of agents reported. Cisplatin is often used in com-
bination with etoposide, vincristine, ifosfamide, or other
agents.51,55
Sinonasal undifferentiated carcinoma. Sinonasal undifferen-
tiated carcinoma (SNUC) is a relatively recently
described pathologic entity representing a rare cancer of
uncertain origin.56 A male predominance is noted with a
wide range of ages at presentation, the median being in
the sixth decade. Patients present with signs and symp-
toms similar to those for other sinonasal malignancies,
including nasal obstruction, epistaxis, proptosis, cranial
nerve involvement, and facial pain,57 and these symptoms
are usually of short duration. Radiographic evaluation fre-
quently reveals a large, locally advanced malignancy
invading into the orbits or intracranially. This is often a
central nasal cavity tumor. The gross pathology, histolo-
gy, and immunohistochemical profile have been described
in a review by Ejaz and Wenig.57 No staging system has
been developed specifically for SNUC, but the Kadish
CLINICAL CONDITION: Esthesioneuroblastoma.
VARIANT 5. Kadish stage C esthesioneuroblastoma initially treated with surgical resection. All lymph nodes were clinically negative.
Treatment Rating Comments
Radiation
Adjuvant RT alone 8 See Ref. 48.
Adjuvant RT with concurrent chemotherapy 5 This option may be appropriate but there was disagreement among panel
members on the appropriateness rating as defined by the panel’s median
rating.
Preoperative RT followed by surgery 5 See Ref. 50.
Preoperative RT and concurrent chemotherapy f
ollowed by surgery
5 This option may be appropriate but there was disagreement among panel
members on the appropriateness rating as defined by the panel’s median
rating. See Ref. 51.
Radiation technique
3D conformal therapy 5
IMRT 8 Proton therapy may be considered in cases in which normal tissue constraints
to critical structures (eg, optic nerves, optic chiasm, spinal cord, brainstem,
etc.) are not achievable using standard IMRT techniques. See Refs. 25, 26,
28, 29, 30.
Target volume
Primary tumor only 7
Primary tumor and ipsilateral neck 5 See Refs. 52, 53, 54.





Rating scale: 1, 2, and 35 usually not appropriate; 4, 5, and 65may be appropriate; 7, 8, and 95 usually appropriate.
Abbreviations: RT, radiotherapy; IMRT, intensity-modulated radiotherapy.
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system has been used in many publications. The prognos-
tic factors for SNUC are not well understood as most
reported series include small numbers of patients. Chen
et al58 evaluated multiple disease-related and treatment-
related parameters, including clinical T classification, age,
primary site, dural involvement, orbit invasion, cranial
nerve involvement, radiation dose and technique, and use
of chemotherapy. None of these was found to be predic-
tive for OS.
A meta-analysis was recently published with individual
data on 167 patients from 30 previously published
series.59 The mean age of patients was 53 years (range,
12–84 years), with 73% being men. Sixty percent had dis-
ease extension beyond the paranasal sinuses. Approxi-
mately 8% to 9% had cervical lymph node metastases at
presentation, and 25% of Kadish group C patients had
metastases at presentation. A majority of patients under-
went surgical resection (53%) either alone or followed by
adjuvant RT with or without chemotherapy. The most
commonly used chemotherapeutic agents were cyclophos-
phamide, doxorubicin, and vincristine. Radiation was part
of the treatment in >80% of the patients. Surgical resec-
tion seemed to confer a survival advantage, and presence
of disease in the neck nodes and Kadish group C were
poor prognostic factors. Overall, trimodality therapy
seemed to be the best treatment option. The role of elec-
tive nodal irradiation is also undefined in SNUC. In a
report from the University of Florida, 7 of 13 patients
with clinically N0 neck at presentation received elective
nodal irradiation and 6 did not. None of the irradiated 7
patients failed regionally, although 2 of the 6 patients
who did not receive elective nodal irradiation failed in
the neck.60 In another series, 15 of 19 patients received
elective nodal irradiation and no neck nodal failures were
noted on follow-up.58
Summary of recommendations
 Upfront surgery is the treatment of choice for all resect-
able lesions. Nasal endoscopic resection should be con-
sidered over open surgery in appropriate cases.
 Adjuvant RT with or without concurrent chemotherapy
is advised based on the presence of adverse pathologic
features. These adverse features are the same as those for
squamous cell carcinomas of other head and neck sites.
 IMRT, with photons or protons, reduces radiation-
induced toxicity and should be preferentially considered
over 3D conformal RT.
 Cisplatin-based concurrent chemotherapy is often used
in patients with unresectable disease, positive margins,
or lymph nodes with extracapsular extension, based on
extrapolation from randomized trials conducted for head
and neck cancer of other subsites.
 The role of induction and intra-arterial chemotherapy is
controversial.
 The benefit and role of elective neck node treatment is
also undefined and controversial. Elective neck manage-
ment is recommended for patients with T3 to T4 squa-
mous cell carcinoma and poorly differentiated carcinoma
of the maxillary sinus.
Summary of evidence
Of the 60 references cited in the ACR Appropriateness
Criteria Nasal Cavity and Paranasal Sinus Cancers docu-
ment, all of them are categorized as therapeutic references
including 3 well-designed studies, 37 good quality stud-
ies, and 5 quality studies that may have design limita-
tions. There are 11 references that may not be useful as
primary evidence. There are 4 references that are meta-
analysis studies.
The 60 references cited in the ACR Appropriateness
Criteria Nasal Cavity and Paranasal Sinus Cancers docu-
ment were published from 1976 to 2013.
Although there are references that report on studies
with design limitations, 40 well-designed or good quality
studies provide good evidence.
TABLES: ACR Appropriateness Criteria Nasal Cavity
and Paranasal Sinus Cancers
Supporting documents
For additional information on the Appropriateness Cri-
teria methodology and other supporting documents go to
www.acr.org/ac.
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